Pipeline Overview
Tengion is developing a diverse pipeline of novel cell and tissue based regenerative medicine therapies for patients who are experiencing organ and tissue impairment, failure and loss. Tengion's technology platform is designed to allow patients to have functioning organs and tissues regenerated from their own cells.
- Tengion Neo-Urinary Conduit™ has initiated a Phase 1 clinical trial in patients with bladder cancer who require a total cystectomy.
- Tengion Neo-Bladder Augment™ has completed two Phase 2 clinical trials in patients with neurogenic bladder: pediatric patients with spina bifida and adult patients with spinal cord injury.
Tengion is leveraging its Organ Regeneration Platform to develop product candidates for urologic, renal, kidney, gastrointestinal, and vascular diseases and conditions.
- Tengion’s Neo-Kidney Augment™ is under development for patients with chronic kidney disease to delay or prevent dialysis.
- Tengion’s Neo-GI Augment™ is aimed at addressing esophageal and intestinal disorders.
- Tengion’s Neo-Vessel Replacement™ is our research program for alternative vascular access for patients undergoing dialysis and patients undergoing coronary or peripheral artery bypass surgery.
Tengion's regenerative medicine product candidates are investigational and will not be commercially available until the completion of clinical trials and the review and approval of associated marketing applications by the FDA.
Click here to check the status of Tengion's Pipeline »